Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2996781 | 0.85 | MAOB (0.59) | MAOBHIF1ASMN1; SMN2 | |
| SCHEMBL2993766 | 0.84 | ALOX15 (0.56) | MAOBHIF1AALOX15ALDH1A1KDM4E | |
| SCHEMBL3000781 | 0.82 | MAOB (0.51) | MAOBHIF1AKMT2A | |
| SCHEMBL17055348 | 0.80 | MAOB (0.47) | MAOBHIF1AKDM4E | |
| SCHEMBL2992355 | 0.79 | MAOB (0.49) | MAOBHIF1ASMN1; SMN2ALOX15ALDH1A1 | |
| SCHEMBL2642966 | 0.77 | PIP5K1C (0.49) | MAOBHIF1AALDH1A1KDM4E | |
| SCHEMBL1674346 | 0.77 | ALDH1A1 (0.63) | MAOBHIF1ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL25337209 | 0.76 | CA12 (0.44) | MAOBHIF1AALOX15 | |
| SCHEMBL29137453 | 0.76 | KDM4E (0.48) | MAOBHIF1ASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL30372357 | 0.76 | SMN1; SMN2 (0.77) | SMN1; SMN2MEN1KMT2AALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276496-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAOB 3222/4885HIF1A 2401/4885SMN1; SMN2 3033/4885 |
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | MAOB 3222/4885HIF1A 2401/4885SMN1; SMN2 3033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.